Navigation Links
Osseon® Therapeutics Introduces New Osseoflex® DR Steerable Bone Drill
Date:10/5/2010

SANTA ROSA, Oct. 5 /PRNewswire/ -- Osseon Therapeutics, Inc. announced its new Osseoflex DR Steerable Bone Drill at the North American Spine Society's (NASS) annual meeting in Orlando, Florida.  The physician-controlled drill was designed to facilitate treatment of vertebral compression fractures (VCFs) that may contain sclerotic bone resulting from osteoporosis or fibrotic metastases.  The Osseoflex DR Steerable Bone Drill features proprietary technology and allows for unipedicular access to fractures previously considered inaccessible due to dense, sclerotic bone or malignant bone tissue.

"Osseoflex DR is an innovation in VCF therapy. It provides an important tool for cases where VCF needles and balloons are currently inadequate," said John Stalcup, Ph.D., Osseon's President and CEO.  According to Michael T. Lyster, M.D., Chief Medical Officer, "The Osseoflex DR Steerable Bone Drill further extends our clinical reach beyond purely acute VCFs.  We can now access chronic and sub-acute symptomatic bone fractures throughout the axial skeleton."

Osseon markets the Osseoflex® Steerable Needle and Osseoperm® Bone Cement for the treatment of vertebral compression fractures.  Together, they form the Osseoplasty System which represents a safe and effective method for the treatment of VCFs.

About Osseon

Osseon Therapeutics, Inc. focuses on bringing to market alternative minimally invasive treatments for degenerative bone and joint disease.  Headquartered in Santa Rosa, CA, the company's groundbreaking technology and delivery system provides comparable or better efficacy and safety than other commercial solutions while offering significant advantages in efficiency and cost. By improving the treatment of compression fractures within the thoracic and lumbar vertebral spine, Osseon offers alternative solutions to patients suffering from these maladies, as well as the physicians and medical facilities that treat them.  Its first-generation products have received both FDA clearance and the CE Mark for product distribution in the United States and European Union.  For more information, visit our web site at www.osseon.com.

Osseon™ is a registered trademark of Osseon Therapeutics, Inc. The names of actual companies and products mentioned herein may be the trademarks of their respective owners.


'/>"/>
SOURCE Osseon Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/5/2017)... 2017   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade cell and tissue hypothermic ... today announced that it has reached an agreement with ... shareholder, to modify its existing credit facility effective June ... WAVI agreed to exchange its existing $4.25 million credit ...
(Date:6/30/2017)... , June 30, 2017 In vitro ... the start of May, at least ten diagnostic companies ... private investments, public offerings and a loan facility.  The ... to almost $80 million.  Kalorama Information provides a monthly ... its Diagnostics Knowledge Center. ...
(Date:6/30/2017)... 29, 2017  Axium Pharmaceuticals Inc. is a pharmaceutical company aimed ... and alternative dosage forms of existing biologically active molecule. ... ... waterless self-nano emulsifying formula, which is designed to prevent precipitation ... the spray will provide fast onset of action and is ...
Breaking Medicine Technology:
(Date:7/23/2017)... ... July 23, 2017 , ... A 20-year-long study ... Louis, and led by the Minneapolis Veterans Administration Health Care System overwhelmingly supports growing ... disease offers very few benefits. , In the cases involved with this study, ...
(Date:7/23/2017)... ... July 23, 2017 , ... Technology ... safety and patient-provider relationships. New tools are helping patients become more actively involved ... Annual Health Care’s Most Wired® survey, released today by the American Hospital Association’s ...
(Date:7/23/2017)... ... July 23, 2017 , ... Viora Ltd., a ... US Patent No. 9,038,640 by the United States Patent and Trademark Office. The ... combination of Switching, Vacuum, and Cooling mechanisms to further increase the efficacy and ...
(Date:7/21/2017)... , ... July 21, 2017 , ... "As a doctor ... lot of pleural catheters available on the market," said an inventor from Center Valley, ... and safety for the patient." , He developed the patent-pending PLEURAL SAFE-t-STAT CATHETER KIT ...
(Date:7/21/2017)... ... July 21, 2017 , ... Roderick Crabbe Insurance, ... to families and business owners in northern Florida, is joining the First Coast ... to area adults with developmental challenges. , The First Coast YMCA offers assistance ...
Breaking Medicine News(10 mins):